← SynDRA
NIRAPARIB
SynDRA canonical compound SYN0021759 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | PARP1 | PARP2 |
|---|
| Mechanism of action | PARP inhibitor |
|---|
| Indication | primary peritoneal cancer (PPC) |
|---|
| Disease area | oncology |
|---|
All known targets
- PARP1
- PARP2
- PARP10
- PARP12
- PARP14
- PARP15
- PARP3
- PARP4
- TNKS
- TNKS2
Mechanisms of action (all sources)
- PARP2 INHIBITOR
- Poly [ADP-ribose] polymerase 2 inhibitor
- PARP1 INHIBITOR
- Poly [ADP-ribose] polymerase-1 inhibitor
- PARP inhibitor
- PARP1 MODULATOR
Drug classes
- Antineoplastic Agents
- Enzyme Inhibitors
- Poly(ADP-ribose) Polymerase Inhibitors
- Poly(ADP-Ribose) Polymerase Inhibitors
- Poly(ADP-Ribose) Polymerase Inhibitor
ATC classes
- L01X · OTHER ANTINEOPLASTIC AGENTS
Cross-references
Synonyms
- niraparib hydrochloride
- niraparib HCl
- MK-4827
- niraparib tosylate monohydrate
- niraparib tosylate
- zejula
- JNJ-64091742
- MK4827
- NIRAPARIB (MK-4827)
- Zejula
- ZL-2306
- MK 4827
- (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
- UNII-HMC2H89N35
- HMC2H89N35
- CHEMBL1094636
- 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide
- Niraparib [USAN:INN]
- 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide
- 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
- MK 4827 (Base)
- Niraparib (USAN)
- Zejula (TN)
- MK-4827(Niraparib)
- SCHEMBL1421875
- GTPL8275
- CTK8B9123
- EX-A290
- DTXSID50146129
- MolPort-023-219-142
- ZINC43206370
- BDBM50316226
- Niraparib Tosylate
- MK-4827 (tosylate)
- MK 4827 tosylate
- UNII-75KE12AY9U
- MK-4827(Niraparib) tosylate
- 75KE12AY9U
Look up NIRAPARIB in the interactive SynDRA portal →